Thermo Fisher Scientific, the National University Hospital (NUH) Singapore, and Mirxes (a Singapore-based RNA technology company) have signed a Memorandum of Understanding (MOU) to collaborate on developing and clinically validating advanced genomic testing solutions tailored for the Southeast Asian population.
The partnership aims to increase access to affordable, advanced next-generation sequencing (NGS) genomic testing for cancer in Singapore and the region. It leverages Thermo Fisher's NGS systems, NUH's clinical expertise, and Mirxes' RNA technology to provide rapid and precise cancer diagnosis, enabling personalized treatment selection for optimized clinical outcomes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.